叶酸受体α与HER2靶向术中荧光引导肿瘤细胞减灭术在上皮性卵巢癌中的可行性:系统综述
本系统综述检索PubMed与Embase,纳入针对上皮性卵巢癌患者或动物模型的FRα或HER2靶向荧光引导细胞减灭术研究。动物研究均能检出肿瘤沉积,一项研究显示荧光引导手术较常规手术残留病灶更少;人体研究肿瘤沉积检出率提高,真阳性75%-77%,假阳性10%-25%,淋巴结为主要假阳性来源,仅一项人体研究报告敏感度85.9%。
要点
- FRα与HER2靶向荧光引导细胞减灭术在动物模型和患者中均可行
- 人体研究真阳性75%-77%、假阳性10%-25%,淋巴结是主要假阳性来源
- 仅一项人体研究报告敏感度85.9%,生存获益尚待验证
核心结论
- FRα或HER2靶向荧光引导细胞减灭术在上皮性卵巢癌动物模型和患者中均显示可行,是有前景的技术,但需进一步研究验证并尤其需要研究生存获益。
研究设计与样本
- 系统综述,检索PubMed与Embase,纳入针对HER2或FRα的上皮性卵巢癌患者或动物模型的荧光引导细胞减灭术研究。
- 分别采用SYRCLE和MINORS工具评估偏倚风险和方法学质量。
主要发现
- 所有针对FRα或HER2的动物研究均能通过术中荧光成像检出肿瘤沉积。
- 一项针对HER2的动物研究比较常规细胞减灭术与荧光引导细胞减灭术,结论为荧光引导手术(无论是否在常规手术后进行)较单纯常规手术残留病灶显著更少。
- 人体荧光引导手术研究显示肿瘤沉积检出率提高,真阳性介于75%-77%,假阳性介于10%-25%,淋巴结是假阳性结果的主要来源。
- 敏感度为85.9%,但仅由一项人体研究报告。
关键数值与推荐
- 上皮性卵巢癌中FRα过表达比例为80%,HER2过表达比例为20%。
- 转移性疾病患者5年相对生存率为30.2%。
- 人体研究真阳性75%-77%,假阳性10%-25%,敏感度85.9%(仅一项研究报道)。
临床怎么用
- 荧光引导细胞减灭术可辅助术中识别肿瘤沉积,可能减少残留病灶,但当前证据主要来自动物研究。
- 假阳性以淋巴结为主,术中判读需结合病理,生存获益尚未证实,不宜作为常规替代标准手术。
局限性
- 人体研究数量有限,敏感度仅由一项研究报道。
- 纳入动物研究,结果外推至临床需谨慎。
- 未提供生存获益数据,仍需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epithelial ovarian cancer (EOC) is often diagnosed late, with a 5-year relative survival of 30.2% for patients with metastatic disease. Residual disease following cytoreductive surgery is an important predictor for poor survival. EOC is characterized by diffuse peritoneal metastases and depositions of small size, challenging a complete resection. Targeted fluorescence imaging is a technique to enhance tumor visualization and can be performed intraoperatively. Folate receptor alpha (FRα) and human epidermal growth factor receptor 2 (HER2) are overexpressed in EOC in 80% and 20% of the cases, respectively, and have been previously studied as a target for intraoperative imaging. OBJECTIVE: To systematically review the literature on the feasibility of FRα and HER2 targeted fluorescence-guided cytoreductive surgery (FGCS) in women with EOC. METHODS: PubMed and Embase were searched for human and animal studies on FGCS targeting either HER2 or FRα in either women with EOC or animal models of EOC. Risk of bias and methodological quality were assessed with the SYRCLE and MINORS tool, respectively. RESULTS: All animal studies targeting either FRα or HER2 were able to detect tumor deposits using intraoperative fluorescence imaging. One animal study targeting HER2 compared conventional cytoreductive surgery (CCS) to FGCS and concluded that FGCS, either without or following CCS, resulted in statistically significant less residual disease compared to CCS alone. Human studies on FGCS showed an increased detection rate of tumor deposits. True positives ranged between 75%-77% and false positives between 10%-25%. Lymph nodes were the main source of false positive results. Sensitivity was 85.9%, though only reported by one human study. CONCLUSION: FGCS targeting either HER2 or FRα appears to be feasible in both EOC animal models and patients with EOC. FGCS is a promising technique, but further research is warranted to validate these results and particularly study the survival benefit.
引用
- de Jong JM, Hoogendam JP, Braat AJAT, et al. The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review. Gynecol Oncol. 2021. PMID: 34053747. doi:10.1016/j.ygyno.2021.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。